Document 0074
 DOCN  M9440074
 TI    Treatment of HIV-1 infection with combination therapy: antiretroviral
       agents + biologic response modifiers (Meeting abstract).
 DT    9404
 AU    Schnittman SM; Div. of AIDS, NIAID, NIH, Rockville, MD
 SO    Biological Response Modifiers, 2nd International Congress. January
       29-31. 1993, San Diego, CA, p. 84, 1993.. Unique Identifier : AIDSLINE
       ICDB/94698356
 AB    HIV-1 infects the CD4+ T lymphocyte population leading to progressive
       decline in immunologic function, and to development of AIDS. Despite the
       activity and clinical benefit of antiretroviral therapies, these agents
       fail to halt the disease progression. Antiretrovirals diminish viral
       replication but result in modest, short-lived increases in CD4+ T cells
       and immune function. These observations support the concept of
       combination therapy with antiretroviral agent + biologic response
       modifier to extend clinical benefits in HIV-infected patients by
       bolstering the immune response against HIV-1, and by preventing the
       selection of drug-resistant viral variants. Several Phase I/II clinical
       trials have demonstrated safety and tolerability as well as antitumor
       and antiviral effects of combination therapy with interferon-alpha +
       zidovudine for patients with AIDS-related Kaposi's sarcoma. In general,
       the best responses are seen in individuals with CD4 cell counts greater
       than 200/mm3. Randomized, controlled Phase III trials are underway to
       determine this combination's clinical efficacy. Preliminary studies of
       combination therapies with zidovudine + interleukin-2 (IL-2), and IL-2 +
       interferon-alpha have demonstrated promising antiviral and immune
       enhancing activities. Areas for future research include CD8+ T cell
       adoptive immunotherapy in combination with IL-2, inhibitors of specific
       cytokines (TNF-alpha, IL-6), and vaccination with HIV viral peptides in
       combination with antiretroviral agents.
 DE    Clinical Trials  HIV Infections/DRUG THERAPY/*THERAPY  Human
       Interferon-alpha/*THERAPEUTIC USE  Interleukin-2/*THERAPEUTIC USE
       Zidovudine/*THERAPEUTIC USE  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).